Pacific Edge Signs First Commercial Agreement in Singapore

1 February 2018 Pacific Edge Signs First Commercial Agreement in Singapore Cancer diagnostics company, Pacific Edge Limited (NZX:PEB) has reached a commercial agreement with Raffles Diagnostica Pte Ltd to offer its suite of Cxbladder tests in Singapore. Under the terms of the agreement, Raffles Diagnostica Pte Ltd, a wholly owned subsidiary of the Raffles Medical Group (RMG) will coordinate the specimen collection, shipping and reporting of Cxbladder tests for RMG urologists for the detection and management of bladder cancer for Raffles' patients in Singapore. This is the first commercial agreement to be signed by Pacific Edge in Singapore, where the company has established a base for its investigation into the opportunity for Cxbladder tests within South East Asia. User Programmes are currently being run in the majority of the large private hospitals in the country and the focus remains on transitioning these into commercial customers once these studies have concluded. Raffles Medical Group is a leading integrated private healthcare provider in Asia, operating medical facilities in 13 cities throughout Singapore, China, Japan, Vietnam and Cambodia and caring for over 2 million patients and more than 6,800 corporate clients each year. RMG is the only private medical provider in Singapore to own and operate a fully integrated healthcare organisation, which includes Raffles Hospital in Singapore. CEO of Pacific Edge, David Darling, commented: "We are delighted to work with the prestigious Raffles Medical Group in Singapore and whilst this is a relatively small commercial proposition for Pacific Edge, it offers a significant stepping stone into the Raffles Medical Group across South East Asia. The region remains an exciting proposition for Pacific Edge with approximately 9,500 urologists and an estimated 1.8 million potential tests." ENDS For more information contact: David Darling Chief Executive Officer Pacific Edge Ltd P: +64 (3) 479 5800 OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and commercialisation of diagnostic and prognostic tests for better detection and management of cancer. Its Cxbladder suite of non-invasive, simple to use and accurate diagnostic tests provide actionable results, and better detection and management of urothelial cancer. The company is developing and commercialising its range of Cxbladder bladder cancer tests globally through its wholly owned central laboratories in New Zealand and the USA. The company's products have been tested and validated in international multi-centre clinical studies. ABOUT Cxbladder Triage www.cxbladder.com Cxbladder Triage combines the power of the genomic biomarkers with additional phenotypic and clinical risk factors to accurately identify patients with haematuria who have a low probability of bladder cancer and may not require a more extensive urological evaluation. Cxbladder Triage is a tool for use by clinicians and physicians in primary evaluation of patients with haematuria and is intended to reduce the need for an expensive and invasive work-up in patients who have a low probability of having urothelial carcinoma. ABOUT Cxbladder Detect www.cxbladder.com Cxbladder Detect enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of a patients' urine. Cxbladder Detect provides clinicians with a quick, cost effective and accurate measure of the presence of the cancer as an effective adjunct to cystoscopy. ABOUT Cxbladder Monitor www.cxbladder.com Cxbladder Monitor allows urologists to monitor bladder cancer patients for recurrence of the disease. Bladder cancer has a recurrence rate of 50-80% and requires life-long surveillance. Cxbladder Monitor accurately identifies patients with a prior history of urothelial cancer (UC) whose Cxbladder Monitor score shows that they have a low probability of recurrent urothelial carcinoma. Cxbladder Monitor is designed to be used as the preferred adjunct test to cystoscopy in the management of patients for ongoing evaluation of recurrent bladder cancer. ABOUT Cxbladder Resolve www.cxbladder.com Cxbladder Resolve identifies those patients who are likely to have aggressive or more advanced bladder cancer. Cxbladder Resolve, when used as part of the primary evaluation of haematuria and/or in conjunction with other Cxbladder tests (Triage, Detect), is designed to assist clinicians by accurately identifying patients with a high probability of having high grade or late stage bladder cancer, for whom alternative or expedited treatment options may be warranted, or who can be prioritised for further investigation in high throughput settings. Refer to www.cxbladder.com for more information. End CA:00313617 For:PEB Type:MKTUPDTE Time:2018-02-01 09:15:00